spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

PCI Builds North American Clinical Sales Team

PCI Pharma Services

Philadelphia, USA – 29 August, 2017




Leading outsourcing services provider PCI Clinical Services has expanded its North American Clinical sales team with the appointment of Nadine DuChateau as Business Development Executive.

Following an extensive career in clinical development services with more than 15 years’ experience in the field, Nadine joins the PCI team to support the development of the company’s client base in the Midwest. Prior to PCI, Nadine spent two years at a leading contract development and manufacturing organization in the pharmaceutical and biotechnology sector.

At PCI, Nadine will be responsible for account management and territory growth for the company’s global clinical packaging and logistics services in the Midwest, maintaining and growing market share with key customers while developing new business and cross-selling PCI’s high potency oral solid manufacturing, commercial packaging and analytical testing services.

Welcoming Nadine to PCI, Tim Roberts, PCI North America Business Development Director, commented: “We are thrilled Nadine will be part of our team. She brings a wealth of experience and has a glowing record of accomplishments that she’s achieved over her career. We are looking forward to working with her here at PCI Clinical Services and her insightful contributions to the success of our clients.”

Nadine said: “I am excited for this new opportunity given PCI’s reputation as the market leader. I’m really looking forward to joining the team and leveraging my experience in my new role to deliver great results for both new and current clients.”

PCI has announced considerable investment in its Clinical Trials business over the past year, including the expansion of its Cold Chain infrastructure at its North American clinical logistics facility in Rockford, IL, expanding onsite cryogenic storage to complement its extensive refrigerated and frozen on-site storage. In addition, the company announced a significant site expansion of its Bridgend, Wales, UK clinical center of excellence, which recently reached practical completion. PCI’s Bridgend site specializes in a broad range of temperature controlled storage and distribution capabilities including cryogenic storage, complementing services at the Rockford site.

These developments follow PCI’s announcement of its site expansion for its drug development and clinical trial manufacturing center of excellence in Tredegar, Wales, UK, including the purchase of a fully contained Xcelodose 600 unit for contained development of potent compounds in early phase clinical study.

To find out more about PCI, please visit www.pciservices.com.

About PCI

The global healthcare industry trusts PCI for the drug development solutions that increase their products’ speed to market and opportunities for commercial success. Only PCI brings the proven experience that comes with more than 50 successful product launches a year and over four decades in the healthcare business. Leading technology and continued investment enables us to address global development needs throughout the product life cycle — from Phase I clinical trials through commercialization and ongoing supply. Our clients view us as an extension of their business and a collaborative partner, with the shared goal of improving patients’ lives. For more information, please visit www.pciservices.com or follow us on Twitter at @PCI_Social.

Contact


Chantel Richman / Fotini Efstathiou at Remarkable Content
chantel.richman@remarkablegroup.co.uk / Fotini@remarkablegroup.co.uk

T: 0117 247 0158 / 01962 853 929
phone +44 (0)1495 713 633
email sales@pciservices.com
web www.pciservices.com
email Wye Valley Business Park, Hay-on-Wye, HR3 5PG
 
Print this page
Send to a friend
   
spacer
News and Press Releases

BBI Solutions broadens antibody portfolio and strengthens reagent technical support capabilities with acquisition of Maine Biotechnology Services

BBI, a leading manufacturer of raw materials and finished test platforms, already provides human antigens, antibodies, serum and plasma products and clinical chemistry enzymes, for the in-vitro diagnostics market. Now with the acquisition of MBS they have strengthened their antibody offering, providing a comprehensive portfolio and custom services to deliver a total reagent solution for any immunoassay development.
More info >>


White Papers

BioT ULT Transporter

BioCision

The growth of biobanking, cell therapy, and complex biopharmaceutical therapies like cancer vaccines has created a strong need for products and processes to ensure the stability of temperature­-sensitive biospecimens. Proper collection, handling, characterization, packaging and shipping of these materials is critical, as poor sample handling impacts researchers working on discovery with patient samples, as well as clinicians treating patients with cutting edge therapies. This white paper describes in detail the BioCision BioT™ ULT Transporter, the first-of-its-kind dry ice-based portable cooling system that maintains a stable -75° to -50°C environment for over 24 hours on one charge of dry ice, enabling reliable handling and transfer of valuable temperature-sensitive biospecimens as part of a larger cold chain standardization process.
More info >>

Industry Events

BioTrinity 2018

23-25 April 2018, Novotel London West in Hammersmith

BioTrinity 2018 is taking place from 23-25 April at the Novotel London West in Hammersmith. Now in its 12th year, BioTrinity remains the leading life sciences biopartnering and investment conference in Europe, and is a must attend event for R&D companies, TTO’s and academia who are looking to meet, collaborate, partner and seek funding from Big Pharma, Investors and Associated Industry companies.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement